Use of aromatase inhibitors in practice of gynecology

Betul Usluogullari, Betül Usluoğullari, Candan Duvan, Candan Zehra Duvan, Celil Alper Usluoğulları, Celil Usluogullari
Journal of ovarian research · 2015 · vol. 8(1) , pp. 4 · doi:10.1186/s13048-015-0131-9 · PMID:25824050 · PMC4350971 · W2142774140
review OA: gold CC0 ⤵ 3 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Aromatase inhibitors show promise for treating estrogen-dependent gynecological diseases, but their use is limited by side effects, cost, and lack of extensive data for infertility treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This paper is a literature review of the use of aromatase inhibitors (AIs) in gynecologic diseases, drawing on the authors’ clinical experience across conditions including endometriosis, leiomyoma, estrogen-dependent gynecologic neoplasia, and infertility. It reports that AIs suppress estrogen production systemically and in endometriotic tissue, with several studies suggesting effective dosing for endometriosis-associated pelvic pain (e.g., anastrazole 1 mg/day and letrozole 2.5 mg/day), reductions in endometrioma size, and potential roles as adjunct therapy in refractory cases; however it emphasizes limitations including lack of large, well-designed randomized controlled trials, ongoing risk of ovarian cysts from induced folliculogenesis, possible bone loss with prolonged use, and possible recurrence of pelvic pain after treatment. For leiomyoma, it describes upregulated aromatase in myoma cells and notes that AIs can reduce uterine leiomyoma size and improve symptoms in the menopausal transition, generally with fewer systemic side effects than some alternatives. This paper is centrally about endometriosis — it evaluates how aromatase inhibitors suppress estrogen synthesis in endometriotic tissue and summarizes evidence for symptom and lesion-size outcomes, while noting the evidence base and trial gaps.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE: The conversion of androgens into estrogens by aromatase is called aromatization and is inhibited by aromatase inhibitors (AIs). The aim of this article is to evaluate the use of aromatase inhibitors in gynecological diseases such as endometriosis, leiomyoma, estrogen- dependent gynecologic neoplasia and infertility. METHODS: This is a review of literature combined with experience and use of aromatase inhibitors ın practıce of gynecology. CONCLUSION: AIs are promising agents in treatment of estrogen dependent disease. However lack of experience, side effects and cost are limiting factors for using these agents in infertility treatment. However there is need for larger, well designed randomized trials to generate robust data in order to establish the true potential of aromatase inhibitors.

My notes (saved in your browser only)

Condition tags

endometriosisinfertility

MeSH descriptors

Aromatase Inhibitors Genital Diseases, Female Aromatase Inhibitors Female Genital Diseases, Female Gynecology Gynecology Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (78)

Cited by (3)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:58.238279+00:00
License: CC0 · commercial use OK